Loading organizations...
LabCorp Venture Fund, based in Burlington, North Carolina, is the corporate venture arm of LabCorp, investing in early-stage private companies developing innovative solutions in clinical diagnostics, drug development, and healthcare. The fund strategically deploys capital into diagnostic innovations, precision medicine, digital health, cell and gene therapy, and point-of-care solutions, to advance healthcare accessibility and affordability. Since its inception in 2012, it has deployed over $300 million across more than 85 direct investments, with 50+ active portfolio companies. Its parent company, LabCorp, a public diagnostics and life sciences firm, reported $12.2 billion in 2023 revenue and employs over 60,000 individuals, led by CEO Adam Schechter. Vaughn Watters represents the fund, established in 2012. The firm focuses on healthcare innovation, clinical diagnostics, drug development, precision medicine, digital health, consumer wellness, and medical device/diagnostics companies.
Key people at LabCorp Venture Fund.
Labcorp Venture Fund is passionate about teaming up with founders and startups to accelerate access to innovative technologies and services. It supports companies that are disrupting the diagnostic landscape and building the future of healthcare.
Yes, Labcorp Venture Fund focuses on companies that are disrupting the diagnostic landscape and developing innovative technologies and services across the healthcare continuum.
Labcorp Venture Fund is passionate about teaming up with founders and startups to accelerate access to innovative technologies and services. It supports companies that are disrupting the diagnostic landscape and building the future of healthcare.
Yes, Labcorp Venture Fund focuses on companies that are disrupting the diagnostic landscape and developing innovative technologies and services across the healthcare continuum.
The fund's investment thesis centers on early-stage private companies that are developing solutions in areas directly relevant to or strategically aligned with Labcorp's operations. By focusing on these specific sectors, Labcorp Venture Fund aims to support innovations that can significantly impact diagnostics and other healthcare services.
Labcorp Venture Fund is particularly passionate about identifying and supporting companies that are disrupting the diagnostic landscape. Its portfolio includes companies that are actively building the future of healthcare, reflecting a commitment to advancing medical science and patient care through strategic venture investments.
Beyond capital, the fund actively engages with its portfolio companies, as evidenced by its recognition of these businesses in various industry accolades. This involvement underscores its role not just as an investor, but as a strategic partner in the growth and success of healthcare innovators.
Key people at LabCorp Venture Fund.
LabCorp Venture Fund has 1 tracked investment across 1 company. The latest tracked deal is $20.0M Series A in Prenosis in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 29, 2026 | Prenosis | $20.0M Series A | PACE Healthcare Capital | Carle, Global Health Investment Corporation, Illinois Department OF Commerce & Economic Opportunity, UCI Health, UC Investments, UCI Health Ventures |
